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MATERIALS AND METHODS
Each participant visited the laboratory once for approximately 3 hours. The visit included medical and smoking history questionnaires, spirometry, blood sample for genetic sequencing, and muscle oxidative capacity test using near-infrared spectroscopy. At the completion of the visit, each participant was provided with a triaxial accelerometer (Dynaport, McRoberts, NL) to wear in the small of the back and held in place by an elastic belt to determine daily step counts.
Spirometry: Approximately 15 minutes before spirometric testing, participants inhaled two puffs of metered dose albuterol sulfate (ProAir HFA, Teva Respiratory, Horsham, PA, USA).
Spirometry was performed in accordance with the American Thoracic Society guidelines (6) using a dual beam Doppler ultrasound-based spirometer (EasyOne Pro, Ndd Medical, Zürich, Switzerland) (9) . Forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) were measured from the greatest FEV 1 and FVC over up to eight maximum expiratory maneuvers, where the greatest two measurements were within 150 mL.
Genetic analyses:
Genotyping for the COPDGene study was performed on the Illumina Human Omni-1 Quad array with imputation using the Haplotype Reference Consortium on the Michigan Imputation Server. Quality control details of the COPDGene genotyping data is given in Appendix 2, Table 2 . SNPs were annotated using wANNOVAR (3, 12, 15) . Linear regression with an additive genetic model was performed to identify the association of k with each of the 11 SNPs, adjusting for age, weight, pulmonary function (FEV 1 % predicted), physical activity (steps/day) and principal components of genetic ancestry using PLINK2.0 (www.coggenomics.org/plink/2.0/; 2). Additional models were run without an adjustment for steps/day. NHW and AA individuals were analyzed separately and results were combined in a fixed-effects meta-analysis in METAL (13) resulting in a total sample size of 152 in the fully adjusted model.
Muscle oxidative capacity:
We applied a protocol recently validated on smokers with and without COPD (1) on the medial gastrocnemius muscle. A continuous-wave, spatially-resolved spectroscopy (SRS) NIRS device (PortaMon, Artinis, The Netherlands) was used to measure the relative concentrations of oxygenated and deoxygenated hemoglobin (HbO 2 and HHb), and the tissue saturation index was determined using the SRS approach (TSI, %) (4). With the participant lying supine, the NIRS probe was placed longitudinally on the belly of the medial Co., Irvine, CA). Following this, a physiological normalization was performed with complete arterial occlusion of the thigh until constant (low) TSI was achieved or 5 minutes, whichever was the sooner. This value was used to normalize NIRS signals to the maximum and minimum physiologic range. After ~5 minutes resting to re-establish baseline hemodynamics, the participant performed two muscle oxidative capacity assessments, each consisting of ~10-15 s sub-maximal rhythmic muscle contractions followed by a series of intermittent arterial occlusions (5 occlusions for 5 s, and 10 for 10 s, each separated by 5-20 s recovery). The two muscle oxidative capacity assessments were separated by ~1-2 minutes of resting recovery. Afterwards the adipose tissue thickness was estimated at the NIRS site using a skinfold caliper (Lange Skinfold Caliper, Beta Technology Inc., Santa Cruz, CA). From the NIRS data relative muscle oxygen consumption (in units of % change in TSI per second) was determined during each post-contraction arterial occlusion and was used to construct muscle oxygen consumption recovery kinetics. The exponential recovery rate constant, k, was characterized using non-linear least squares fitting, as preciously described (Origin 8.6, OriginLab, MA, USA; 1). Muscle oxygen consumption recovery k is linearly associated with muscle oxidative capacity (10, 14).
Daily step counts by triaxial accelerometry:
Physical activity was assessed objectively using a a portable triaxial accelerometer (DynaPort ADL-monitor, McRoberts BV, NL) that has been validated in healthy, elderly and COPD patients (5, 7, 8, 11) . At the end of the clinic visit, participants received instructions on wearing the monitoring device around their waist for 7 consecutive days. Participants were instructed to wear the DynaPort accelerometer for 24 hours per day, and only to remove it for bathing. Valid measurements were determined by at least 94% wearing compliance within a total of at least five 24-hour periods. After completion of the 7 th day of wearing the device was delivered back to laboratory for data download and analysis using the manufacturer's algorithms (MoveMonitor version 2.8). Abbreviations: rsID -dbSNP rsID; locus name, variant annotation; Chr -chromosome; Pos -Build 37 position; EA/ALT -Effect allele and alternative allele; Trait, Gastroc kGastrocnemius muscle oxygen consumption recovery rate constant (k); EAF -Effect allele frequency; β (SE)/Z-score -effect estimate and standard error for a quantitative trait and Z-score for example for a binary trait; P -P-value for association; N -number of samples analyzed Abbreviations: rsID -dbSNP rsID; locus name, variant annotation; Chr -chromosome; Pos -Build 37 position; EA/ALT -Effect allele and alternative allele; Trait, Gastroc kGastrocnemius muscle oxygen consumption recovery rate constant (k); EAF -Effect allele frequency; β (SE)/Z-score -effect estimate and standard error for a quantitative trait and Z-score for example for a binary trait; P -P-value for association; N -number of samples analyzed Abbreviations: rsID -dbSNP rsID; locus name, variant annotation; Chr -chromosome; Pos -Build 37 position; EA/ALT -Effect allele and alternative allele; Trait, Gastroc kGastrocnemius muscle oxygen consumption recovery rate constant (k); EAF -Effect allele frequency; β (SE)/Z-score -effect estimate and standard error for a quantitative trait and Zscore for example for a binary trait; P -P-value for association; N -number of samples analyzed Figure S1 . The effect on muscle oxygen consumption recovery rate constant (k) of T/C genetic variation on rs2792022 BTAF1 among all subjects in study, those without COPD and those with moderate-to-severe COPD stratified by genetic ancestry. AA (circle) = African American. NHW (triangle) = Non-Hispanic White. Meta-analysis between genetic ancestry (square). Subjects with COPD were those with moderate-to-severe disease (FEV 1 /FVC<0.7 and FEV 1 %predicted <80%). Error bars in forest plot show 95% confidence intervals. Figure S2 . The effect on muscle oxygen consumption recovery rate constant (k) of G/A genetic variation on rs6481619 SVIL among all subjects in study, those without COPD and those with moderate-to-severe COPD stratified by genetic ancestry. AA (circle) = African American. NHW (triangle) = Non-Hispanic White. Meta-analysis between genetic ancestry (square). Subjects with COPD were those with moderate-to-severe disease (FEV 1 /FVC<0.7 and FEV 1 %predicted <80%). Error bars in forest plot show 95% confidence intervals. Figure S3 . The effect on muscle oxygen consumption recovery rate constant (k) of G/A genetic variation on rs7386139 DEPTOR among all subjects in study, those without COPD and those with moderate-to-severe COPD stratified by genetic ancestry. AA (circle) = African American. NHW (triangle) = Non-Hispanic White. Meta-analysis between genetic ancestry (square). Subjects with COPD were those with moderate-to-severe disease (FEV 1 /FVC<0.7 and FEV 1 %predicted <80%). Error bars in forest plot show 95% confidence intervals .
